Read More

Reported Late Thursday March 9, MediciNova Announces Additional Extension Of BARDA Contract To Develop MN-166 As A Medical Countermeasure Against Chlorine Gas-induced Lung Injury; Contract Was Amended To Extend The Period Of Performance Until May 31, 2…

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced a modification to its contract with

MNOV

Read More

Reported Late Monday, MediciNova Receives A Notice Of Allowance For A New Patent Covering MN-001 And MN-002 For The Treatment Of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia In Brazil

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance

MNOV

Read More

Reported Late Tuesday, MediciNova Announces Additional Results Regarding The Effects Of MN-001 On Serum Lipid Panel In Type 2 Diabetes And NAFLD Patients Presented At IDF 2022 Congress, The Annual Meeting Of The International Diabetes Federation

ediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova's Chief Medical

MNOV

Read More

MediciNova Received a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-001 (tipelu

MNOV